SILAC Analysis Reveals Increased Secretion of Hemostasis-Related Factors by Senescent Cells. by Wiley, Christopher D et al.
Lawrence Berkeley National Laboratory
Recent Work
Title
SILAC Analysis Reveals Increased Secretion of Hemostasis-Related Factors by Senescent 
Cells.
Permalink
https://escholarship.org/uc/item/42s9b8zk
Journal
Cell reports, 28(13)
ISSN
2211-1247
Authors
Wiley, Christopher D
Liu, Su
Limbad, Chandani
et al.
Publication Date
2019-09-01
DOI
10.1016/j.celrep.2019.08.049
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
SILAC Analysis Reveals Increased Secretion of Hemostasis-
Related Factors by Senescent Cells
Christopher D. Wiley1,7, Su Liu1,7, Chandani Limbad1, Anna M. Zawadzka1, Jennifer Beck1, 
Marco Demaria2, Robert Artwood1, Fatouma Alimirah1, Jose-Alberto Lopez-Dominguez1, 
Chisaka Kuehnemann1, Steven R. Danielson1, Natan Basisty1, Herbert G. Kasler1, Tal 
Ronnen Oron1, Pierre-Yves Desprez1,3, Sean D. Mooney4, Bradford W. Gibson5, Birgit 
Schilling1, Judith Campisi1,6,*, Pankaj Kapahi1,8,*
1Buck Institute for Research on Aging, Novato, CA 94945, USA 2European Institute for the 
Biology of Aging, University of Groningen, Groningen, the Netherlands 3California Pacific Medical 
Center, Research Institute, San Francisco, CA 94107, USA 4Department of Biomedical 
Informatics & Medical Education, University of Washington, Seattle, WA 98195, USA 5Discovery 
Attribute Sciences, Amgen Inc., South San Francisco, CA 94080, USA 6Biosciences Division, 
Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA 7These authors contributed 
equally 8Lead Contact
SUMMARY
Cellular senescence irreversibly arrests cell proliferation, accompanied by a multi-component 
senescence-associated secretory phenotype (SASP) that participates in several age-related 
diseases. Using stable isotope labeling with amino acids (SILACs) and cultured cells, we identify 
343 SASP proteins that senescent human fibroblasts secrete at 2-fold or higher levels compared 
with quiescent cell counterparts. Bioinformatic analysis reveals that 44 of these proteins 
participate in hemostasis, a process not previously linked with cellular senescence. We validated 
the expression of some of these SASP factors in cultured cells and in vivo. Mice treated with the 
chemotherapeutic agent doxorubicin, which induces widespread cellular senescence in vivo, show 
increased blood clotting. Conversely, selective removal of senescent cells using transgenic 
p163MR mice showed that clearing senescent cells attenuates the increased clotting caused by 
doxorubicin. Our study provides an in-depth, unbiased analysis of the SASP and unveils a function 
for cellular senescence in hemostasis.
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In Brief
Wiley et al. identify new proteins secreted by senescent cells using unbiased proteomics, including 
factors involved in hemostasis. Secretions of senescent cells increase human platelet activation, 
while eliminating senescent cells prevents increases in platelet counts and activation in mice 
treated with chemotherapy. Senescent cells may thus underlie clotting predisposition.
Graphical Abstract
INTRODUCTION
Cellular senescence permanently arrests cell proliferation in response to a variety of stresses, 
including DNA damage, mitochondrial dysfunction, and oncogene activation (Campisi, 
2013; Wiley et al., 2016). Senescent cells participate in a wide range of biological processes 
(Childs et al., 2015; Muñoz-Espín and Serrano, 2014), playing beneficial or deleterious 
roles, depending on the triggers of senescence, as well as the tissue and cell types. Senescent 
cells accumulate with age and drive a variety of age-related pathologies, at least in mice 
(Baar et al., 2017; Baker et al., 2016; Chang et al., 2016). The senescence response can 
impair tissue regeneration (Chang et al., 2016; Jeon et al., 2017) and promote cancer cell 
proliferation and invasion (Krtolica et al., 2001; Laberge et al., 2015). In contrast, 
senescence suppresses tumorigenesis (Prieur and Peeper, 2008), accelerates wound healing 
(Demaria et al., 2014), and fine-tunes embryogenesis (Muñoz-Espín et al., 2013; Storer et 
al., 2013). Although the mechanisms are incompletely understood, senescent cells exert 
some of these effects by secreting numerous growth factors, cytokines, chemokines, and 
proteases, known as the senescence-associated secretory phenotype (SASP) (Acosta et al., 
2013; Coppé et al., 2008; Kuilman et al., 2008).
To better understand the biological consequences of cellular senescence, we embarked on a 
comprehensive, unbiased method to profile the SASP using stable isotope labeling with 
amino acids (SILACs), a mass spectrometry-based technique that uses non-radioactive, 
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stable isotope labeling of cells. Surprisingly, this screen revealed several SASP factors, 
expressed by cells induced to senesce by DNA damage, that were predicted to participate in 
hemostasis.
Hemostasis is a tightly regulated, complex process that prevents excessive bleeding after 
injury. Hemostasis has primary and secondary major components. Primary hemostasis forms 
a platelet plug at the injured site. Upon vascular damage, platelets adhere to the injured 
vessel, become activated, and aggregate to arrest bleeding (Tanaka et al., 2009; Versteeg et 
al., 2013). However, because the primary plug is not stable, secondary hemostasis then 
stabilizes the clot by depositing insoluble fibrin, which is generated by the coagulation 
cascade. These two processes happen simultaneously and interact in a dynamic fashion. 
Multiple anti-clotting mechanisms, such as circulating anticoagulants and fibrinolysis, which 
removes the plug after the vessel is repaired, also play critical roles in hemostasis (Tanaka et 
al., 2009; Versteeg et al., 2013). An impaired balance between pro- and anti-elements of 
coagulation can lead to pathological bleeding or, conversely, thrombosis.
An increased risk for thrombosis is a common age-associated complication and major risk 
factor for mortality (Sepúlveda et al., 2015). Thrombosis is also a common side effect of 
radio- and genotoxic chemotherapies, which significantly increase the risk for post-therapy 
mortality and decrease quality of life (Bosch et al., 2014; Vergati et al., 2013). Though it is 
known that DNA-damaging cancer therapies induce cellular senescence (Demaria et al., 
2017; Ewald et al., 2010), an association between cellular senescence and thrombosis has 
not yet been made.
Our finding that the secretion of a subset of hemostasis-related factors increases significantly 
when human fibroblasts undergo senescence suggests that senescent cells may contribute to 
the etiology of age- and genotoxic therapy-induced thrombosis. We show that senescent cells 
promote blood clotting in mice treated with the genotoxic anti-cancer chemotherapeutic 
doxorubicin, whereas removing senescent cells from such mice attenuates clotting. 
Furthermore, the pro-coagulation effect of senescent cells is associated with both increased 
platelet number and reactivity. Our findings identify an additional function of senescent cells 
and provide potentially important insights into genotoxic therapy-induced thrombosis.
RESULTS
SILAC Analysis Identifies a Potential Role for the SASP in Hemostasis
To obtain an unbiased profile of the SASP, we used SILACs to analyze conditioned media 
(CM) from quiescent and senescent primary human foreskin (HCA2) fibroblasts. Figure 1A 
and Figure S1A show the timeline for 13C6 lysine and 13C6 arginine labeling of quiescent 
cells and the schedule for inducing senescence in unlabeled cells by ionizing radiation (IR) 
and CM collection. We analyzed three independent biological replicates for each condition 
and confirmed the senescent and quiescent states by SA-β-gal staining and BrdU labeling 
(Figures S1B–S1C). The proteins we identified, and the magnitude of changes in secreted 
levels between quiescent and senescent cells, are shown in Tables S1A–S1C. Overall, we 
detected 1,047 proteins, identified by at least two peptides per protein, with 99% confidence 
(Table S1A).
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Among the SASP factors we identified, 343 showed a significant (>2-fold) increase in 
abundance in CM from senescent, compared with quiescent, cells (Table S1B). Reactome 
bioinformatic analyses showed that, notably, 5 of the top 25 pathways (highlighted in Figure 
1B) were associated with hemostasis, blood clot formation, or clot dissolution. The SASP 
factors predicted to be hemostasis related by Reactome, and the magnitude of their changes, 
are presented as two heatmaps in Figure 1C. The left heatmap shows factors that are the 
most highly elevated (most yellow), and the right shows the second most highly elevated. 
Additional bioinformatic analyses identified the molecular functions, cellular components, 
and biological processes in which they are known to participate (Figures S1D–S1F). 
Together, the results suggest the SASP might include hemostasis-related factors.
We also observed increases in extracellular matrix (ECM) proteins in our initial dataset, 
which might warrant additional study (Figure 1B; Figures S1D–S1F). However, the 
concurrent increased secretion of proteinases may have artificially increased the abundance 
of peptides derived from the ECM. For this reason, we chose to focus on hemostasis.
Validation of SILACs Results in Cultured Cells
To validate the SILAC results, we collected CM from three independent cultures of 
quiescent or IR-induced senescent HCA2 cells and determined by western blotting the levels 
of 11 hemostasis-related factors identified by SILACs (Figure 1D). These factors included 
vinculin (VCL), tissue inhibitor of metalloproteinase 1 (TIMP1), tissue factor pathway 
inhibitor (TFPI), thrombospondin 1 (THBS1), calumenin (CALU), serpin E1 (SERPINE1, 
PAI1), serpin E2 (SERPINE2), serpin B2 (SERPINB2, PAI2), serpin B6 (SERPINB6), 
filamin A-alpha (FLNA), and EH domain containing 2 (EHD2). All were present at 
increased levels in CM from senescent, compared with quiescent, cells in all three replicates, 
consistent with the SILAC results. These factors play important roles in regulating 
hemostasis. For example, THBS1 is a major protein released from platelets during 
activation, where it stimulates platelet aggregation by blocking nitric oxide/cGMP signaling 
(Isenberg et al., 2008).
Because thrombosis is a common unwanted side effect of genotoxic cancer treatments 
(Ashrani et al., 2016; Huang et al., 2011; Zagar et al., 2016), we compared factors from 
quiescent cells and cells induced to senesce by doxorubicin (DOXO), a DNA-damaging 
chemotherapeutic. Elevated secretion of many SASP factors correlates with increased 
mRNA abundance of the respective genes (Coppé et al., 2008). Indeed, mRNAs encoding 
several hemostasis-related factors increased after DOXO treatment (Figure 2A). We 
confirmed the induction of hemostasis-related genes upon senescence in another primary 
human fibroblast strain, WI-38 (Figure S2A). Because blood is more likely to be exposed to 
senescent vascular cells, we also tested senescent human umbilical vein endothelial cells 
(HUVECs) for ability to produce these factors (Figure S2B). In agreement with previous 
work (Coppé et al., 2008), the patterns were not identical. However, the expression of 
several major hemostasis factors increased upon irradiation of HUVECs, similar to 
fibroblasts, though PLAU, PLAUR, and FLNA were each lower in senescent HUVECs. 
Moreover, western blots of CM from DOXO-induced senescent HCA2 cells showed 
increased hemostatic SASP factors relative to quiescent controls, similar to IR-induced 
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senescence (Figure 2B). Finally, DOXO can also deplete mtDNA. We therefore tested the 
levels of these factors in mitochondrial dysfunction-associated senescence (MiDAS) induced 
by mtDNA depletion (Wiley et al., 2016). Many hemostasis-related factors were also 
elevated in MiDAS (Figure 2C), indicating that multiple drivers of senescence potentially 
affect hemostasis.
Senescence-Stimulated Induction of Hemostasis-Related Genes In Vivo
To determine whether the senescence-associated increased expression of hemostasis-related 
genes occurs in vivo, we used p16–3MR transgenic mice, which allow the detection of 
senescent cells by luminescence and their removal by ganciclovir (GCV) (Demaria et al., 
2014). Following systemic administration of DOXO, senescent cells increased, as measured 
by elevated luminescence and p16INK4a mRNA levels (Figures S3A and S3B) in the liver, a 
key organ that generates hemostasis-related factors, and these senescent cells were 
efficiently eliminated by GCV (Demaria et al., 2017). Importantly, mRNA levels of the 
hemostasis-related genes Serpine1, Serpine2, Thbs1, Plau, Flna, and Timp1 were also 
elevated by DOXO and reduced by GCV (Figure 3A).
We extracted platelet-poor plasma from each treatment group and measured Thbs1 (Figure 
3B, left panel), Serpine1 (Figure 3B, right panel), uPA (Figure S3C, right panel), and Timp1 
(Figure S3C, left panel). Each factor increased after DOXO treatment and declined upon 
removal of senescent cells by GCV. Moreover, mRNAs encoding senescence (p16INK4a and 
Il6) (Figure S3D) and hemostasis-related factors were elevated in livers of aged mice (24–25 
months old compared with 4–6 months old) (Figures S3D and S3E).
Senescent Cells Lower Tail Bleed Times
To determine whether senescent cells affect hemostasis in vivo, we analyzed tail bleeding 
times in DOXO- or PBS-treated p16–3MR mice receiving GCV or vehicle. DOXO-treated 
mice showed significantly shorter bleeding times relative to control mice. Importantly, after 
eliminating senescent cells, tail bleeding times were similar to those of control mice (Figure 
4A). We also determined the amount of blood lost in the tail bleeding time assay by 
measuring hemoglobin levels (Figure 4B). Consistent with the tail bleeding time assays, 
DOXO-treated mice had the lowest blood loss, which was prevented by GCV. Because red 
blood cell counts were similar among the treatment groups (Table S2), lower hemoglobin in 
DOXO-treated mice was not due to anemia but rather to faster clotting.
Finally, platelet counts increased in response to DOXO and returned to baseline levels when 
DOXO-treated mice were treated with GCV, indicating that the increased platelet counts 
were senescence dependent (Figure 4C). Plasma from DOXO-treated mice showed increased 
thrombopoietin (Tpo), which drives thrombopoiesis, and this increase was also senescence 
dependent (Figure 4D). Despite this observation, we found no evidence for changes in the 
burden of senescent cells or hemostatic factors in bone marrow derived from treated mice 
(Figure S4A), suggesting that the effect of senescent cells on coagulation is not driven by 
changes in the marrow environment. Consistent with this suggestion, we found no changes 
in maturation when megakaryocytes were removed from the marrow of each group and 
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cultured separately, indicating that secreted factors, rather than megakaryocytes themselves, 
drove this effect (Figure S4B).
Senescent Cells Sensitize Platelets to Activation
Clotting is regulated primarily by platelet activation and the coagulation cascade (Semple et 
al., 2011). To determine whether senescent cells affect platelet activation in vivo, we 
compared platelets in the blood of DOXO- or vehicle-treated p16–3MR mice that were 
subsequently given GCV or vehicle. We used collagen to activate the platelets and measured 
P-selectin positivity (Figure 4E) and exposed phosphatidylserine (assessed by annexin V 
binding) (Figure 4F), markers of platelet activation, using flow cytometry. Collagen 
activated a greater number of platelets from DOXO-treated mice relative to controls; 
importantly, GCV blunted this increase in activated platelets.
To determine whether the SASP affects platelet activation, we incubated freshly isolated 
human platelets with CM from the quiescent or IR-induced senescent human cells 
(described in Figure 1) and the platelet activator collagen. We then measured platelet-
released ATP, a marker of activation (Beigi et al., 1999). Platelets exposed to CM from 
senescent cells showed greater activation than platelets exposed to quiescent cell CM (Figure 
4G), indicating that the SASP can prime platelets for activation.
Finally, we asked whether senescent cells affect the coagulation cascade. We measured 
activated partial thromboplastin time (APTT) and prothrombin time (PT) in each treatment 
group (Quality Veterinary Laboratory, Davis, CA). There were no significant differences 
between DOXO- and PBS-treated p16–3MR mice (Figures S4C and S4D), suggesting that 
senescent cells do not affect the coagulation cascade. Because many factors identified in our 
analysis can accelerate the coagulation cascade (e.g., serpins, uPA), it is likely that the 
factors that promote platelet activation (e.g., THBS1) play a more important role in the 
promotion of hemostasis by senescent cells. Together, the data indicate that senescent cells 
influence clotting time primarily by increasing platelet number and sensitizing them to 
activation.
DISCUSSION
The SASP can promote cancer cell proliferation and metastasis (Coppé et al., 2008; Krtolica 
et al., 2001; Laberge et al., 2015), reinforce senescence (Acosta et al., 2013), and optimize 
wound healing (Demaria et al., 2014) and embryonic development (Muñoz-Espín et al., 
2013; Storer et al., 2013). Thus, investigating the complete SASP profile is critical to 
determine the biological functions of senescent cells. A previous study identified SASP 
factors from oncogene-induced senescent cells using SILACs (Acosta et al., 2013). We 
found 32 proteins in common between this study and ours, accounting for ~10% of the total 
SASP factors we identified and ~25% of the secretome identified by the previous study. The 
differences between these SASP profiles may be due to the differences in cells, collection 
time, sample handling protocol, and senescence stimuli. Recent data suggest that cellular 
senescence is not a singular homogeneous state but rather an evolving heterogeneous 
phenotype regulated with spatiotemporal specificity (Demaria et al., 2014; Hoare et al., 
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2016). Thus, future genomic and proteomic studies will be needed to explore different 
stimuli, time points, and cell types.
Our SILAC results suggest a role for the SASP in hemostasis. Indeed, senescent cells 
promoted blood clotting, most likely by sensitizing platelets to agonists rather than 
activation of the coagulation cascade. Platelet activation is associated with thrombotic 
disease (Gurbel et al., 2016; Ruggeri, 2002), and anti-platelet therapy has been used to 
prevent and treat cerebrovascular, coronary, and peripheral arterial diseases (Michelson, 
2010; Steinhubl et al., 2014; Tran and Anand, 2004). Chemotherapy is a major risk factor for 
thrombotic disorders, including stroke (Huang et al., 2011), cardiovascular disease (Zagar et 
al., 2016), and venous thromboembolism (Ashrani et al., 2016). Although there is a 4.1-fold 
greater risk for thrombosis in cancer patients, chemotherapy increases this risk to 6.5-fold 
(Heit et al., 2000), with as yet no clear explanation. DOXO was previously shown to 
increase platelet activation in vitro, but the role of senescent cells in this process was not 
studied (Kim et al., 2011). Because genotoxic chemotherapies are known to induce cellular 
senescence (Demaria et al., 2017; Ewald et al., 2010), our findings suggest that 
chemotherapy-induced senescence could potentiate blood clotting, possibly by modifying 
platelet function. They also suggest that SASP-suppressing adjuvant therapies might reduce 
this side effect of chemotherapy.
The SASP is a multi-component phenotype that entails the secretion of dozens of 
biologically active factors (Acosta et al., 2013; Coppé et al., 2008; Kuilman et al., 2008). 
Our findings suggest that the SASP also regulates homeostasis-related factors, among other 
biological activities. However, the precise mechanisms by which senescent cells sensitize 
platelets for activation remain to be determined. Because senescent cells accumulate with 
age, it is tempting to speculate that the SASP is at least partly responsible for the thrombotic 
events that increase with age. These indications are potential targets for the development of 
senolytic drugs, which can selectively eliminate senescent cells (Chang et al., 2016), similar 
to the action of GCV in p16–3MR mice.
STAR★METHODS
LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by Pankaj Kapahi (pkapahi@buckinstitute.org). p16–3MR mice are shared for 
research and educational purposes under an MTA that will be discussed in good faith with 
the recipient.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Culture—HCA2 are normal primary human neonatal foreskin fibroblasts (originally 
obtained from Dr. Pereira-Smith, University of Texas Health Science Center, San Antonio, 
TX). WI-38 and IMR-90 are normal primary human embryonic lung fibroblasts (obtained 
from the American Type Culture Collection). Fibroblasts were cultured in DMEM plus 10% 
FBS and penicillin/streptomycin, at 3% oxygen and 10% CO2. HUVECs were obtained 
from the American Type Culture Collection and grown in F-12K medium plus 10% FBS, 
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penicillin/streptomycin, heparin, and endothelial cell growth supplement (BD Biosciences 
#354006). Senescence was induced by exposing sub-confluent cultures to 10 Gy X-
irradiation (IR) or 250 nM doxorubicin (DOXO); control cultures were mock irradiated or 
treated with vehicle. Quiescence was induced by culture in 0.2% serum for 3 days. 
Quiescent cells were used 3 d after mock irradiation or vehicle treatment; senescent cells 
were used 7–10 d after irradiation or DOXO treatment. Media were changed every other day. 
On the 9th day, cells were incubated in serum-free medium and CM was collected 24 h later. 
For mitochondrial dysfunction-associated senescence (MiDAS), IMR-90 fibroblasts were 
cultured in the presence of ethidium bromide (100 ng/mL) until senescent, as described 
(Wiley et al., 2016).
Animal Experiments—All protocols were approved by the Buck Institution Animal Care 
and Use Committee. Young (4–7 months old) p16–3MR male mice were given PBS 
(vehicle) or DOXO (10 mg/kg) by intraperitoneal (i.p.) injection. Seven days later, they were 
given, also by i.p. injection, PBS (vehicle) or ganciclovir (GCV; 25 mg/kg) once per day for 
5 consecutive days to clear senescent cells, as described (Demaria et al., 2014).
For tail bleeding assays, male mice (p16–3MR in C57BL/6, 3–5 months old) were 
anesthetized, and the tail was transected 5 mm from the tip with a razor blade. The bleeding 
tail was immersed in a 15 mL test tube containing saline pre-warmed to 37°C, and time to 
cessation of blood flow was measured. Bleeding times were determined when the bleeding 
stopped for 10 s. Bleeding times exceeding 6 min were noted as 6 min. The amount of 
bleeding was quantitated by measuring the hemoglobin content of blood collected into the 
saline using a Hemoglobin Assay Kit (Sigma Aldrich, St. Louis, MO), following the 
manufacturer’s instructions.
METHOD DETAILS
Antibodies—Antibodies against the following proteins were used (see also Key Resource 
Table): BD Pharmigen – P-selectin (553744); Abgent – CALU (AP12308b-ev), EHD2 
(aw5422-EV), PLAU (AP8161b-ev), SERPINE2 (AP12607c-ev20); Bethyl – FLNA (A301–
134A-T); Biolegend – CD41 (133905), Annex-V-APC (640920); R&D Systems – MINDIN 
(AF2609), SERPINB2 (MAB85501), SERPINB6 (AF4336), SERPINE1 (MAB1786), TFPI 
(AF2974), THBS1 (AF3074), TIMP1 (AF970), VCL (MAB6896).
SA-β-Gal and BrdU Labeling—We detected SA-β-Gal as described (Dimri et al., 1995), 
using a commercial kit (BioVision). Briefly, 30,000 cells per well were seeded on a 12-well 
plate. Cells were fixed using 500 μL Fixing Buffer for 10 min, followed by three washes in 
PBS, and overnight incubation at 37°C in Staining Solution. Cells were visualized and 
counted using an inverted microscope.
DNA synthesis was determined using a modified BrdU labeling kit (Roche #11296736001). 
Cells were cultured in BrdU (20 μM in DMSO) for 24 hours, fixed in 4% neutral-buffered 
formalin for 10 min, and washed 3 times in ice cold PBS. Permeabilization was perform for 
30 min by incubation in 0.5% Triton X-100 in PBS. Nuclear DNA was digested by a 
combination of DNase I and exonuclease III for 1 hour, and BrdU-containing fragments 
were visualized by immunofluorescence.
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Reagents and Standards—HPLC solvents, including acetonitrile and water, were 
obtained from Burdick & Jackson (Muskegon, MI). Reagents for protein chemistry, 
including iodoacetamide, dithiothreitol (DTT), ammonium bicarbonate, formic acid, and 
urea, were purchased from Sigma Aldrich (St. Louis, MO). Proteomics grade trypsin was 
from Promega (Madison WI). HLB Oasis SPE cartridges were purchased from Waters 
(Milford, MA). SILAC heavy lysine Lys-6 (13C6, 99%) and Arg-6 (13C6, 99%) were 
obtained from Thermo Scientific (Waltham, MA).
SILAC Sample Preparations—Non-senescent cells were grown in heavy SILAC 
medium, and senescent (irradiated) cells were incubated in light SILAC medium, both with 
3 biological replicates (for details see Figure S1A). Quiescent HCA2 cells were cultured in 
DMEM medium supplied with L-Lys-13C6 and L-Arg-13C6 (heavy medium) for 6 passages 
to achieve complete label incorporation (~99%) before seeding (Day 0), according to the 
vendor’s recommendation. At least 5 passages prior to the experiment, incorporation 
efficiency of the heavy labeled amino acids into proteins was assessed in a pilot experiment, 
where a small aliquot of intracellular protein was lysed, reduced, alkylated, and trypsin 
digested and subjected to MS analysis as described below. Heavy label incorporation into 
proteins from non-senescent cells was assessed as >99%. Senescent (irradiated) HCA2 cells 
were cultured in DMEM complete medium (light medium) (for details see Figure S1A).
For the proteomics, 24 h before harvesting, plated cells were washed 3 times with fresh fetal 
calf serum (FCS)-free medium for 10 min at 37°C each. The cells were then incubated in 
FCS-free medium (12 mL per flask) for 24 h at 37°C. At the end of the culture period, cells 
showed no evidence of apoptosis. CM was collected as described above, and centrifuged at 
1,200 g for 5 min. The supernatant was transferred to fresh tubes. CM from quiescent and 
senescent cells were mixed based on equal cell numbers, and concentrated (~1:100 fold) 
using Millipore centrifugal filter units (MWCO 3.5 kDa). Samples were prepared for mass 
spectrometric analysis including removal of phenol red dye by buffer exchange with 50 mM 
TrisCl (pH8.0) (5 washing steps using spin columns at × 5000 g). CM were denatured with 6 
M urea, reduced with 20 mM DTT (30 min at 37°C), alkylated with 50 mM iodoacetamide 
(30 min at RT), and digested overnight at 37°C with 1:50 enzyme:substrate ratio (wt/wt) of 
sequencing grade trypsin (Promega, Madison, WI) as described (Keshishian et al., 2007). 
Following digestion, samples were acidified with formic acid and desalted using HLB Oasis 
SPE cartridges (Waters, Milford, MA). Protein/peptide recovery was not specifically 
assessed; however the above sample preparation and digestion protocol was thoroughly 
assessed for reproducibility during previous optimization and reproducibility studies.
Hydrophilic Interaction Liquid Chromatography (HILIC) peptide fractionation was 
performed on a Waters 1525 HPLC system equipped with a 4.6 × 25 mm TSK gel Amide-80 
HR 5 μm column (Tosoh Bioscience, South San Francisco, CA). CM (~900 μg of protein) 
were loaded in 80% solvent B (98% acetonitrile, 0.1% TFA) and eluted with the following 
gradient: 80% B for 5 min followed by 80% B to 60% B in 40 min, 0% B in 5 min at 0.5 ml/
min. Solvent A consisted of 98% HPLC grade water and 0.1% TFA collecting nine 
fractions.
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Mass Spectrometry—Samples were analyzed by reverse-phase HPLC-ESI-MS/MS using 
an Eksigent Ultra Plus nano-LC 2D HPLC system (Dublin, CA) connected to a quadrupole 
time-of-flight TripleTOF 5600 (QqTOF) mass spectrometer (SCIEX). Typically, mass 
resolution for MS1 scans and corresponding precursor ions was ~35,000 (TripleTOF 5600), 
while resolution for MS/MS scans and resulting fragment ions (MRM-HR transitions) was 
~15,000 (‘high sensitivity’ product ion scan mode) (Schilling et al., 2012). Briefly, after 
injection, peptide mixtures were transferred onto the analytical C18-nanocapillary HPLC 
column (C18 Acclaim PepMap100, 75 μm I.D. × 15 cm, 3 μm particle size, 100 Å pore size, 
Dionex, Sunnyvale, CA) and eluted at a flow rate of 300 nL/min using stepwise gradients 
from 5% to 80% solvent B with total runtimes, including mobile phase equilibration, of 90 
min. Solvent mobile phase A was 2% acetonitrile/ 98% of 0.1% formic acid (v/v) in water, 
and mobile phase B was 98% acetonitrile/2% of 0.1% formic acid (v/v) in water. Data 
acquisition was performed in data dependent acquisition (DDA) mode on the TripleTOF 
5600 to obtain MS/MS spectra for the 30 most abundant precursor ions (50 msec per 
MS/MS) following each survey MS1 scan (250 msec), yielding a total cycle time of 1.8 s as 
described (Kuhn et al., 2014; Schilling et al., 2012).
Bioinformatic Database Searches and SILAC Quantification—MS data were 
searched using the database search engine ProteinPilot (5) (SCIEX Beta 4.5, revision 1656) 
with the Paragon algorithm (4.5.0.0, 1654). The search parameters were set as follows: 
trypsin digestion, cysteine alkylation set to iodoacetamide, SILAC Quantification (Lys-6, 
Arg-6, no bias correction), and Homo sapiens as species. Trypsin specificity was assumed as 
C-terminal cleavage at lysine and arginine. Processing parameters were set to “Biological 
modification” and a thorough ID search effort was used. During the search, Protein Pilot 
performs an automatic mass recalibration of the datasets based on highly confident peptide 
spectra. Specifically, a first search iteration was done to select high confidence peptide 
identifications to recalibrate both the MS and MS/MS data, which is subsequently 
automatically re-searched. During the iterative steps of re-searching the data, the search 
parameters are less stringent, e.g., allowing for additional ‘missed cleavages’ (with typically 
not more than 2).
All data files were searched using the SwissProt 2014_01 release, released January 22, 
2014), with a total of 40,464 human ‘reviewed’ protein sequences searched. A cut-off 
peptide confidence value of 99 was chosen, and a minimum of 2 identified peptides per 
protein was required. The Protein Pilot false discovery rate (FDR) analysis tool, the 
Proteomics System Performance Evaluation Pipeline (PSPEP algorithm) provided a global 
FDR of 1% and a local FDR at 1% in all cases. For protein quantification comparing 
proteins from 3 biological replicate experiments between CM from senescent (light) versus 
quiescent (heavy) cells a Protein Pilot significance threshold of < 0.05 was required. All 
database search results and details for peptide identifications and protein quantification are 
provided in Table S1.
Functional Analysis, Protein Ontology, Pathway Enrichment Analysis—For 
functional analysis and protein ontology analysis, ‘The Database for Annotation, 
Visualization and Integrated Discovery’ (DAVID v.6.7) was used (Huang et al., 2007). For 
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pathway enrichment analysis, we used the Benjamini correction as adjustment to P values to 
determine statistical significance (Figures S1D–S1F).
Western Blotting—CM were collected and stored at −80°C, and cells remaining on the 
culture dish were counted for normalization. Protein concentrations were measured using 
Bradford reagents. Samples were incubated at 95°C for 10 min, loaded on 4%–15% gradient 
tris-glycine SDS-polyacrylamide gels (Invitrogen), separated by electrophoresis and 
transferred to PVDF membranes. Membranes were blocked in TBST/BSA for 1 h at room 
temperature, probed overnight at 4°C with primary antibodies in blocking buffer, washed in 
TBST and incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h at 
room temperature. Signals were detected using Supersignal® West chemiluminescent 
substrate (Thermo Scientific). Densitometry was performed using ImageJ by the 
measurement of area under the curve method following background subtraction.
Platelet Activation Assay—Platelet-associated adenosine triphosphate (ATP) secretion 
was measured using the CHRONO-LUME reagent (Chrono-Log, Havertown, PA), according 
to the manufacturer’s protocol with minor variations. Human platelet-rich plasma was 
incubated in CM from quiescent or IR-induced senescent HCA2 fibroblasts in the presence 
or absence of 5 μg/mL collagen for 10 min prior to analysis. ATP was measured by adding 
CHRONO-LUME luciferin to platelet-rich plasma at a ratio of 1:9, after which 
luminescence was measured on a Perkin Elmer Victor X3 multilabel plate reader.
Isolation of Bone Marrow from Mouse Femurs—Femurs were isolated from both 
legs of each mouse and cut at top and bottom to uncover the bone marrow. The bones were 
flushed with cold PBS using a 25-gauge needle to collect the bone marrow into 1.6 mL 
Eppendorf tubes. Collected samples were centrifuged at 300 × g for 5 minutes at 4°C. After 
centrifugation, the supernatant was removed, and the remaining pellet lysed in 1mL 
TRIzol® reagent for total RNA isolation. RNA isolation was performed according to the 
manufacturer’s instructions (Direct-zol RNA Miniprep Zymo Research cat# R2051).
Megakaryocyte Preparation—Megakaryocytes (MKs) were obtained and analyzed 
according to published protocols (Mathur et al., 2004; Schulze, 2012) with minor 
modifications. C57BL6 mice receiving different treatments were euthanized 8 days after 
treatment, and bone marrow cells were obtained from femurs and tibias by flushing. Single-
cell suspensions were prepared by passage through 25-gauge needles, and collected by 5 
min centrifugation at 200 × g. Cells were cultured in DMEM supplemented with 10% fetal 
bovine serum, 2 mM L-glutamine, penicillin/streptomycin, and 100 ng/ml murine 
thrombopoietin for 10 days. MK ploidy was measured by double staining with FITC 
conjugated anti-CD61 antibody and propidium iodide followed by flow cytometry on a BD 
FACSAria II flow cytometer (Becton Dickinson). CD 61+ cells (regarded as MKs) were 
gated and analyzed for DNA content.
ELISAs—Platelet poor plasma from each treatment group was analyzed by ELISA 
according to the manufacturer’s instructions. Thbs1 was from LifeSpan Biosciences, 
SerpinE1 (PAI-1) was from Abcam, uPA was from Innovative Research, and Timp1 was 
from R&D Systems. Plasma samples were diluted with Assay Buffers before analysis 
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(Thbs1 = 1:5 dilution, PAI-1 = 1:5 dilution, uPA = 1:2 dilution, Timp1 = 1:2 dilution). 
Thrombopoeitin (Tpo) was measured by ELISA (R&D Systems) on undiluted EDTA-treated 
plasma according to the manufacturer’s instructions.
Quantitative PCR—RNA was extracted from cells using the ISOLATE II RNA mini kit 
(Bioline #BIO-52073), following the manufacturer’s instructions. RNA was isolated from 
tissues via the Direct-zol RNA MiniPrep Kit (Zymo #11–331) according to the 
manufacturer’s instructions. RNA (500 ng) was reverse-transcribed using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems #4368813). For each qPCR reaction, 
10 ng of cDNA was used and quantified on a LightCycler 480 II (Roche) for 45 cycles. All 
signals were normalized to beta-actin.
FACS Analysis—Blood was collected from control and treated mice in TBS/Heparin 
(20U/ml), diluted in Tyrode’s buffer, and centrifuged at 900 x g for 5 min. The pellet was 
resuspended in Tyrode’s buffer for further analysis. For measurement of platelet surface 
exposure of P-selectin or phosphatidylserine, we followed published protocols with minor 
modifications (Dachary-Prigent et al., 1993; Nieswandt et al., 2004). Briefly, washed blood 
was diluted 1:25 with Tyrode’s buffer containing 1mM Cacl2, left unstimulated or activated 
with 5 ug/ml type I collagen (Chrono-log) in the presence of a FITC-conjugated mouse anti-
CD62P IgG (BD Biosciences) monoclonal antibody, Annex-V-APC (Biolegend, San Diego, 
CA). Within 30 min, samples were measured by flow cytometry on a FACS Aria II (BD 
Biosciences). No aggregation was observed in this time frame. For platelet counts, 
fluorescent beads (Thermo-Fisher #C36950) were added to volume equivalents of EDTA-
treated blood diluted 1: in ice-cold PBS, which allowed normalization of platelet counts per 
unit volume.
Complete Blood Count (CBC), Activated Partial Thromboplastin Time (APTT), 
and Prothrombin Time (PT)—EDTA-treated blood (CBC) or citrated plasma (APTT/PT) 
was provided to a commercial research organization (Quality Veterinary Laboratory - Davis, 
CA). All assays were performed according to company protocols.
QUANTIFICATION AND STATISTICAL ANALYSIS
Error bars on all graphs show the standard error of the mean from at least three independent 
experiments for culture experiments, and at least 7 mice for animal experiments. The p 
values on single comparisons were performed by t test, while multiple comparisons were 
calculated using one-way ANOVA with Tukey’s post-test. Numbers (n) for each experiment 
are indicated in figure legends, or individual sample plots are indicated. Significance is 
represented as * = p < 0.05, ** = p < 0.01, and *** = p < 0.001, with specific tests and 
significance markers indicated in each relevant figure.
DATA AND CODE AVAILABILITY
The mass spectrometric raw data associated with this manuscript can be downloaded from 
MassIVE at ftp://MSV000079131@massive.ucsd.edu (username: MSV000079131).
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• An unbiased SILAC screen identifies >300 proteins secreted by senescent 
human cells
• Forty-four of these proteins have reported roles in hemostasis
• Conditioned media from senescent cells promotes platelet activation
• Eliminating senescent cells ameliorates pro-coagulation side effects of 
doxorubicin
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Figure 1. SILAC Analysis Suggests a Role for the SASP in Hemostasis
(A) A schematic outlining the strategy for SILAC-based identification of SASP proteins. See 
Figure S1 for time lines of how cells were made quiescent or senescent and how quiescent 
and senescent conditioned media (CM) were produced.
(B) Reactome pathway analysis of proteins secreted at >2-fold levels by senescent compared 
with quiescent HCA2 cells. Pathways related to hemostasis are identified by boxes.
(C) Heatmap showing individual levels of proteins, identified by SILACs, that participate in 
hemostasis and are secreted by quiescent (QUI) and senescent (SEN [IR]) HCA2 normal 
human fibroblasts.
(D) CM were collected from quiescent (QUI) and senescent (SEN [IR]) cells, concentrated, 
and analyzed using western blotting for the indicated SASP factors. Cells remaining on the 
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plate at the time of CM collection were counted for normalization. Mindin protein levels and 
Ponceau S staining were used as loading controls.
Fold changes are mean ± SEM. *p < 0.05 and **p < 0.01.
See also Figure S1 and Table S1.
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Figure 2. Doxorubicin Induces Expression of Hemostasis Factors
(A) mRNA was extracted from HCA2 cells made quiescent (QUI) or induced to senesce by 
doxorubicin (SEN [DOXO]), and analyzed using qPCR for the indicated genes, using actin 
mRNA for normalization. The data are shown in a.u., and the bars show mean ± SEM. *p < 
0.05 and **p < 0.01, two-tailed, unpaired t test.
(B) CM were collected from cells treated as in (A), concentrated and analyzed using western 
blotting for the indicated SASP factors. Cells were counted for normalization. Mindin 
protein levels and Ponceau S staining were used as loading controls.
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(C) IMR-90 fibroblasts were depleted of mtDNA by culture in ethidium bromide until 
senescent (21 days) (labeled as MiDAS). RNA was extracted and analyzed using qPCR for 
the indicated factors. Heatmap represents individual values for three experiments.
*p < 0.05, one-way ANOVA.
See also Figure S2.
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Figure 3. In Vivo Detection of the Hemostatic SASP
Young (4–7 months old) p16–3MR mice were given PBS (control) or DOXO (10 mg/kg) by 
intraperitoneal (i.p.) injection. After 7 days, they were also given PBS (control) or 
ganciclovir (GCV; 25 mg/kg, i.p.) once per day for 5 consecutive days to clear senescent 
cells, as described (Demaria et al., 2014).
(A) RNA was extracted from the liver of treated mice and analyzed using qPCR for mRNA 
levels of the indicated genes. a.u. values were normalized to actin mRNA.
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(B) Platelet-poor plasma from each treatment group was analyzed using ELISA for Thbs1 or 
Serpine1.
All bars show mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001, one-way ANOVA 
with Tukey’s post test. n ≥ 7 for all experiments.
See also Figure S3.
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Figure 4. Senescent Cells Reduce Tail Bleeding Time and Prime Platelet Activation
(A–F) Young (4–7 months old) p16–3MR mice were given PBS or DOXO followed by PBS 
or GCV as described for Figure 3.
(A) Transected tails were submerged in 37°C saline, and time to bleeding cessation was 
measured. The data are expressed as mean ± SEM for 15 to 30 mice per group.
(B) Blood loss was quantified by measuring the hemoglobin (Hb) content of saline from the 
tail bleeding assays in a.u.
(C) Platelet counts from whole blood extracted from mice.
(D) Thrombopoietin ELISA from plasma obtained from the indicated mice.
(E and F) Whole blood was isolated from the animals, washed, stimulated with collagen, and 
analyzed using flow cytometry for cell surface P-selectin (E) and exposed 
phosphatidylserine (F). Data are expressed as the percentage of P-selectin-positive cells (E) 
and annexin V (which specifically binds phosphatidylserine) positive cells (F).
(G) Human platelet-rich plasma was incubated with CM from quiescent (CMQUI) or IR-
induced senescent (CMSEN) cells without or with collagen (+Col) for 10 min. Released ATP 
was measured by luminescence over 5 min. The value for CMQUI was set arbitrarily at 1.
Bar graphs show mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 by one-way 
ANOVA with Tukey’s post test for all experiments.
See also Figure S4 and Table S2.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
p-selectin BD-PharMingen 553744
CALU Abgent AP12308b-ev
EHD2 Abgent aw5422-EV
PLAU Abgent AP8161b-ev
SERPINE2 Abgent AP12607c-ev20
FLNA Bethyl A301–134A-T
CD41 Biolegend 133905
Annex-V-APC Biolegend 640920
MINDIN R&D Systems AF2609
SERPINB2 R&D Systems MAB85501
SERPINB6 R&D Systems AF4336
SERPINE1 R&D Systems MAB1786
TFPI R&D Systems AF2974
THBS1 R&D Systems AF3074
TIMP1 R&D Systems AF970
VCL R&D Systems MAB6896
Chemicals, Peptides, and Recombinant Proteins
Acetonitrile Burdick & Jackson 015
Formic acid Sigma-Aldrich F0507
HPLC grade water Burdick & Jackson 365
Dulbecco’s modified eagle medium (DMEM) Fisher Scientific 21–063–029
F-12K medium ATCC 30–2004
Fetal bovine serum (FBS) Fisher Scientific 16140
Endothelial cell growth supplement BD Biosciences #354006
Ethidium bromide Thermo Scientific 15585–011
Doxorubicin Sigma-Aldrich D1515
Ganciclovir Sigma-Aldrich G2536
Penicillin/Streptomycin Genesee Scientific 25–512
Iodoacetamide Sigma-Aldrich I1149
Dithiothreitol (DTT) Sigma-Aldrich 43815
Ammonium bicarbonate Sigma-Aldrich 09830
Urea Sigma-Aldrich GE17–1319–01
Sequencing Grade Modified Trypsin Promega V5111
L-Arginine-HCl, 13C6, 15N4 for SILAC Thermo Scientific 89990
L-Lysine-2HCl, 13C6 for SILAC Thermo Scientific 89988
Amicon® Ultra-15 Centrifugal Filter Unit EMD Millipore UFC900308
UltraPure 1M Tris-HCI, pH 8.0 Thermo Scientific 15568025
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REAGENT or RESOURCE SOURCE IDENTIFIER
TSKgel® Amide-80 HPLC Column Sigma-Aldrich 813071
Acclaim PepMap 100 C18 LC Columns Thermo Scientific 160321
Collagen Chrono-Log 385
CountBright Absolute Counting Beads Thermo Scientific C36950
Propidium iodide Life Technologies P3566
L-Glutamine Life Technologies 25030081
Recombinant Mouse Thrombopoietin Protein R&D Systems 488-TO
Ponceau S solution Sigma Life Science P7170
Critical Commercial Assays
Senescence Detection Kit BioVision K320
5-Bromo-2′-deoxy-uridine Labeling and Detection Kit Roche #11296736001
CHRONO-LUME® Chrono-Log 395
Mouse THBS1 / Thrombospondin-1 ELISA Kit 
(Sandwich ELISA)
LifeSpan Biosciences LS-F12876
Mouse PAI1 ELISA Kit Abcam ab197752
Mouse uPA ELISA Kit Innovative Research IMUPAKT
Mouse TIMP-1 Quantikine ELISA Kit R&D Systems MTM100
Mouse Thrombopoietin Quantikine ELISA Kit R&D Systems MTP00
ISOLATE II RNA mini kit Bioline BIO-52073
Direct-zol RNA MiniPrep Kit Zymo 11–331
High Capacity cDNA Reverse Transcription Kit Applied Biosystems 4368813
Deposited Data
Raw data from this study (MSV000079131) MassIVE ftp://MSV000079131@massive.ucsd.edu 
(password:winter)
Experimental Models: Cell Lines
HCA2 foreskin fibroblasts Olivia Pereira-Smith N/A
Wi38 fibroblasts ATCC CCL-75
HUVEC-C endothelial cells ATCC CRL-1730
IMR-90 fibroblasts ATCC CCL-186
Experimental Models: Organisms/Strains
p16–3MR mouse in C57BL/6 background Judith Campisi N/A
Oligonucleotides
RT-PCR Primers and UPL Probes See Table S3 N/A
Software and Algorithms
ProteinPilot SCIEX Beta 4.5 Revision 1656
SwissProt UniProt Knowledgebase 2014_01 release
The Database for Annotation, Visualization and 
Integrated Discovery
https://david.ncifcrf.gov/ v6.7
GO enrichment analysis http://geneontology.org 2014 release
ImageJ https://imagej.nih.gov/ 1.52d 11 June 2018
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